---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178950"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:44:22.996614+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Erasca Q2 2025 net loss $33.9M; cash $386.7M; INDs cleared for two RAS drugs

## Summary
- Net loss of $33.9M ($0.12/sh) for Q2 2025, down from $63.2M ($0.29/sh) in Q2 2024.
- Cash, equivalents, and marketable securities $386.7M as of June 30, 2025; expected to fund operations into H2 2028.
- IND cleared for pan-KRAS inhibitor ERAS-4001 (Jun 2025) and pan-RAS molecular glue ERAS-0015 (May 2025); Phase 1 trials ongoing.
- Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.
- R&D expenses $21.2M in Q2 2025 vs $33.0M in Q2 2024, driven by lower impairment and personnel costs.

## SEC filing metadata
- accession: 0001193125-25-178950
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/0001193125-25-178950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/eras-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178950
- JSON: https://secwatch.observer/filing/0001193125-25-178950.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.